

# Detection of Three Distinct Patterns of T Helper Cell Dysfunction in Asymptomatic, Human Immunodeficiency Virus-Seropositive Patients

## Independence of CD4<sup>+</sup> Cell Numbers and Clinical Staging

Mario Clerici,\* Naomi I. Stocks,\* Robert A. Zajac,† R. Neal Boswell,† Daniel R. Lucey,† Charles S. Via,\* and Gene M. Shearer\*

\*Experimental Immunology Branch, Division of Cancer Biology and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892; and †HIV Unit/SGHMMM, Lackland Air Force Base, Texas 78236

### Abstract

We have tested the T helper cell (T<sub>H</sub>) potential of asymptomatic, HIV seropositive (HIV<sup>+</sup>) patients, using an *in vitro* assay for IL-2 production. Peripheral blood leukocytes (PBL) from 74 HIV<sup>+</sup> patients and 70 HIV<sup>-</sup> control donors were tested for T<sub>H</sub> function when stimulated with influenza A virus (FLU), tetanus toxoid (TET), HLA alloantigens (ALLO), or PHA. Of the HIV<sup>+</sup> patients, four different response patterns were observed: (a) patients who responded to all four stimuli (16%); (b) patients who were selectively unresponsive to FLU and TET, but responded to ALLO and PHA (54%); (c) patients who were unresponsive to FLU, TET, or ALLO, but responsive to PHA (16%); and (d) patients who failed to respond to any of these stimuli (14%). Our results indicate a time-dependent progression from a stage responsive to all four stimuli to a stage unresponsive to any of the stimuli tested, progressing in the order outlined above.

The earliest T<sub>H</sub> defect is the loss of responses to FLU and TET, indicating a selective defect in CD4<sup>+</sup> MHC self-restricted T<sub>H</sub> function. The later loss of ALLO and PHA IL-2 responses suggests more severe T<sub>H</sub> dysfunction involving both CD4<sup>+</sup> and CD8<sup>+</sup> T cells. None of these patterns of T<sub>H</sub> unresponsiveness in asymptomatic HIV<sup>+</sup> individuals were correlated with CD4<sup>+</sup> cell numbers nor with Walter Reed staging criteria. This study indicates that the *in vitro* T<sub>H</sub> assay used can detect multiple stages of immune dysregulation early in the course of HIV infection and raises the possibility that staging of HIV<sup>+</sup> patients should include *in vitro* T<sub>H</sub> functional analyses of the type described here.

### Introduction

It is well established that the T lymphocyte-mediated immune defects in patients with AIDS are associated with a severe reduction in the number of CD4<sup>+</sup> T lymphocytes (1–5). Furthermore, it is considered that the loss of CD4<sup>+</sup> T cells is the result of infection with HIV, although the mechanism(s) by which HIV depletes CD4<sup>+</sup> T cells has not been determined. However,

before a severe depletion of CD4<sup>+</sup> cells, a long period without apparent syndrome progression can ensue between the time of infection and development of AIDS symptoms (6–10). This period is characterized by near normal numbers of CD4<sup>+</sup> cells, absence of symptoms, positive delayed skin reactions, and positive *in vitro* proliferative responses to antigenic and mitogenic stimuli, and can be followed by a progressive and sometimes rapid deterioration resulting in symptomatic AIDS.

Early detection of HIV-induced, immune-related changes is important for identification and understanding of the initial events leading to HIV-associated immune dysregulation. Furthermore, detection of early changes in immune parameters would be useful for timing of therapeutic intervention as well as for monitoring immunologic changes that might result from therapy. Early indicators of progression toward AIDS include reduced numbers of CD4<sup>+</sup> cells, a decline of antibodies specific for HIV viral proteins, and an appearance of viral antigens (1–10). In a previous study, we observed that PBL from some otherwise asymptomatic HIV seropositive (HIV<sup>+</sup>) individuals exhibited a defect in cytotoxic T lymphocyte (CTL)<sup>1</sup> responses to influenza A virus, but not to HLA alloantigens (11). These results can be explained by a defect in CD4<sup>+</sup> T helper cell (T<sub>H</sub>) function, even though CD4<sup>+</sup> cell numbers were not critically reduced in these patients.

In the present report we have assessed T<sub>H</sub> function by using an *in vitro* assay for IL-2 production. PBL from Walter Reed Stage 1 (WR 1) and 2 (WR 2) patients were stimulated with influenza virus (FLU), tetanus toxoid (TET), alloantigens (ALLO), and PHA. This panel of stimuli was selected for study because T<sub>H</sub> responses to FLU and TET have been recently shown to be MHC self-restricted and require CD4<sup>+</sup> T<sub>H</sub> and autologous antigen-presenting cells (APC). In contrast, the T<sub>H</sub> responses to ALLO and PHA can utilize both CD4<sup>+</sup> and CD8<sup>+</sup> T cells (11–13).<sup>2</sup> Using this approach, we have identified three categories of T<sub>H</sub> dysfunction among HIV<sup>+</sup> patients whose clinical stages were WR 1 or WR 2. These findings may be valuable as a prognostic indicator for progression toward symptomatic AIDS.

### Methods

*Patients and clinical evaluation.* HIV<sup>+</sup> patients were obtained from Wilford Hall United States Air Force (USAF) Medical Center, Lackland Air Force Base, TX. Individuals were diagnosed as being HIV

Address reprint requests to Dr. Shearer, Experimental Immunology Branch, National Cancer Institute, Building 10, Room 4B17, National Institutes of Health, Bethesda, MD 20892.

The present address of Dr. Via is Rheumatology Division, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201.

Received for publication 20 April 1989 and in revised form 31 July 1989.

1. *Abbreviations used in this paper:* ALLO, alloantigens; CTL, cytotoxic T lymphocyte; FLU, influenza virus; LSM, lymphocyte separation medium; TET, tetanus toxoid; T<sub>H</sub>, T helper cell; WR 1 and WR 2, Walter Reed stages 1 and 2.

2. Via, C. S., G. Tsokos, N. I. Stocks, M. Clerici, and G. M. Shearer, manuscript submitted for publication.

infected if they had anti-HIV antibodies demonstrated on two specimens tested by the HIV enzyme immunoassay (Abbott Laboratories, Irving, TX) and confirmed by Western blot analysis (Roche Biomedical Laboratories, Burlington, NC). Western blots were considered positive if they showed at least two of the following three bands reactive: p24, gp41, and gp120 or gp160. Patients were classified according to the Walter Reed staging system (14). The HIV<sup>-</sup> control donors were USAF personnel of the same sex and with the same age range as the HIV<sup>+</sup> donors.

Lymphocyte counts and T cell subsets were determined using laser-based flow cytometry (Coulter Epics Profile; Coulter Electronics, Inc., Hialeah, FL) and OKT4A (anti-CD4) and OKT8 (anti-CD8) monoclonal antibodies (Orthodiagnostics Systems, Raritan, NJ).

Skin testing for recall antigens was performed using intradermal injections of 0.02 ml of PPD (5TU) (Connaught Laboratories, Ontario, Canada), *Candida albicans* (1/500) (Hollister-Stier, Spokane, WA), Tri-cophyton (1/500) (Hollister-Stier, Spokane, WA), tetanus toxoid (1/5), and mumps (full strength) (both from Connaught Laboratories).

*In vitro tests for T<sub>H</sub> function.* Whole blood from HIV<sup>-</sup> and HIV<sup>+</sup> individuals was drawn in Vacutainer tubes containing preservative-free heparin (Becton-Dickinson & Co., Rutherford, NJ) and shipped from Lackland, TX to Bethesda, MD overnight at ambient temperature. PBL were separated on lymphocyte separation medium (LSM; Organon Teknika Corp., Durham, NC), washed twice in PBS, and resuspended at  $3 \times 10^6$ /ml in RPMI 1640 (Gibco Laboratories, Grand Island, NY) containing 0.5% penicillin and 1% glutamine. The number of viable cells was determined by trypan blue exclusion and hemacytometer. For IL-2 production, 1 ml of PBL was added per well to 24-well flat-bottom Linbro tissue culture plates (Flow Laboratories, Inc., McLean, VA). For the proliferative assay, 0.1 ml of PBL was added per well, in triplicate wells, to 96-well flat-bottom tissue culture plates (Costar, Cambridge, MA). The PBL were cultured without stimulation or were stimulated with (a) influenza A/Bangkok RX73 (at a final dilution of 1:1,000) as previously described (11); (b) tetanus toxoid (at a final dilution of 40 lf/ml) (Massachusetts Department of Health, Boston, MA); (c) a pool of irradiated (5,000 rad) PBL from two or more unrelated HIV<sup>-</sup> donors ( $2 \times 10^6$ /well for IL-2 production and  $2 \times 10^5$ /well for proliferation); and (d) PHA (Gibco Laboratories) diluted 1:200. Pooled AB<sup>+</sup> plasma was added to each well (final dilution 1:20). Supernatants of stimulated and unstimulated cultures were harvested 7 d later and frozen at  $-20^\circ\text{C}$ . For studies of IL-2 production, the anti-IL-2 receptor antibody, monoclonal anti-TAC (a kind gift from Dr. T. A. Waldmann, Metabolism Branch, NCI, NIH, Bethesda, MD), was added at the initiation of culture at a final concentration of 10  $\mu\text{g}/\text{ml}$ , in order to block IL-2 consumption (15). The supernatant IL-2 activity was assessed as the ability to stimulate the proliferation of the IL-2-dependent cell line, CTLL. Assay cultures consisted of  $8 \times 10^3$  CTLL/well and five successive twofold dilutions of supernatant. 24 h later, the cultures were pulsed with 1  $\mu\text{Ci}$  of [<sup>3</sup>H]thymidine (ICN Radiochemicals, Irving, CA) and harvested 18 h later. Results are expressed as mean counts per minute for three replicate wells for a given supernatant dilution. Standard errors were always < 10% of the mean values. For each IL-2 assay, a standard titration curve was determined using recombinant IL-2. However, we were not able to accurately calculate IL-2 units because many of the IL-2 titration curves generated by antigenic stimulation of PBL from immune deficient HIV<sup>+</sup> donors were flat and were not parallel to the standard curves nor the curves generated by PBL from the HIV<sup>-</sup> controls. Therefore, in Figs. 1, 3, and 4, we show the entire titration curves.

For the proliferative assay, cultures were pulsed with 1  $\mu\text{Ci}$  of [<sup>3</sup>H]thymidine 6 d after sensitization and harvested 18 h later. For both assays, thymidine incorporation was determined using a model LS1801  $\beta$ -spectrometer (Beckman Instruments, Fullerton, CA).

*Determination of responsive and unresponsive patients.* For both the IL-2 and proliferative assays, patients were defined as responsive to a given antigen if the mean cpm of their stimulated cultures was > 3 SD above the mean unstimulated cpm of the HIV<sup>-</sup> control donors. The cutoff value for IL-2 production was 7,300 cpm and was derived

from a mean of 70 HIV<sup>-</sup> donors. Supernatant dilutions of both 1:2 and 1:4 were used for determination of responsiveness for the IL-2 assay. The cutoff value for proliferation was 3,138 cpm and was derived from a mean of 58 HIV<sup>-</sup> donors.

*Statistical analysis of data.* Row (R)  $\times$  column (C) contingency tables were set up as shown in Tables I and II for testing possible correlations of the four different T<sub>H</sub> functional categories with CD4<sup>+</sup> cell numbers or WR staging (16). The sum of the  $\chi^2$  value was calculated by the sums of the equation  $\chi^2 = (f - F)^2/F$ , where  $f$  is the observed frequency and  $F$  is the expected frequency. The degrees of freedom for this analysis are:  $df = (R - 1)(C - 1)$ . Student's  $t$  tests were performed for the comparisons of two independent samples of unequal size as described by Snedecor and Cochran (16), and  $P$  values were determined.

## Results

*Patterns of T<sub>H</sub> responses in WR 1 and WR 2 patients.* PBL from 70 HIV<sup>-</sup> control donors and 74 HIV<sup>+</sup> WR 1 and 2 patients were tested for in vitro IL-2 production after stimulation with FLU, TET, ALLO, or PHA. The complete IL-2 titration curves for each of these stimuli are presented in Fig. 1 for two HIV controls (Fig. 1, A and F), four WR 1 patients (Fig. 1, B-E), and four WR 2 patients (Fig. 1, G-J). The data on these patients were selected from the group of 74 to illustrate four different patterns of IL-2 responsiveness. The first pattern, observed in both WR 1 and WR 2 patients (Fig. 1, B and G), is characterized by positive IL-2 responses to all four stimuli. In the second pattern, PBL from WR 1 and WR 2 patients (Fig. 1, C and H) generated near normal IL-2 responses to ALLO and PHA, but failed to produce IL-2 in response to FLU and TET. In the third pattern, PBL from the WR 1 and WR 2 patients (Fig. 1, D and I) responded to PHA but failed to respond to FLU, TET, and ALLO. Finally, PBL from the WR 1 and WR 2 patients (Fig. 1, E and J) failed to respond to any of these stimuli. These results indicate that four different states of T<sub>H</sub> function can be identified within WR 1 and WR 2 patients. Furthermore, the failure of WR 1 and WR 2 patients to respond to any combination of these stimuli did not appear to be correlated with CD4<sup>+</sup> cell numbers (see below).

Using the criteria described in Methods, we determined the number of individuals in the group of 74 patients and 70 controls who responded to FLU, TET, ALLO, or PHA by IL-2 production. We also tested 49 of these same patients and 58 of the controls for proliferative responses to the same stimuli. The numbers and percentages of patients and controls who were unresponsive to each of the stimuli by either of the two T<sub>H</sub> tests are presented in Table I. 62 of the 74 HIV<sup>+</sup> donors (84%) failed to respond to FLU or TET by the IL-2 test. A much lower proportion of these donors was unresponsive to ALLO (30%), and an even lower proportion was unresponsive to PHA (14%). In contrast, only one HIV<sup>-</sup> control donor was unresponsive to FLU and TET, and none of the controls was unresponsive to ALLO or PHA. There was an exact concordance among individuals for both IL-2 and proliferative responses to FLU and TET. Again, similar to the IL-2 data, fewer patients failed to respond to ALLO than to FLU or TET, and even fewer did not respond to PHA. The percentage of HIV<sup>-</sup> controls that was unresponsive to FLU and TET was 1% as measured by IL-2 production and 3-5% by proliferation. All of the controls responded to ALLO and PHA by both assays. For convenience, we shall refer to those patients who re-




Figure 1. IL-2 production by PBL from two HIV<sup>-</sup> control donors (A and F), four WR 1 HIV<sup>+</sup> individuals (B-E), and four WR 2 HIV<sup>+</sup> individuals (G-J). The PBL from these donors were unstimulated (MED,  $\nabla$ ) or were stimulated with FLU ( $\bullet$ ), TET ( $\circ$ ), ALLO ( $\blacktriangle$ ), or PHA ( $\triangle$ ). The titration curves represent the dilutions of culture supernatant used to stimulate the CTLL.

sponded to all four stimuli as +/+ (FLU and TET/ALLO/PHA); to those who failed to respond to FLU and TET, but responded to ALLO and PHA as -/+; to those who failed to respond to FLU, TET, and ALLO, but responded to PHA as -/-; and to those who did not respond to any of the stimuli as -/-/. It should be noted that no patients were found who (a) responded to FLU or TET but not to ALLO or PHA; or (b) did not respond to PHA but were responsive to any of the other three stimuli. These results are compatible with a pattern of sequential progression from +/+ to -/+, to -/-, and finally to -/-/.

Fig. 2 lists the frequencies of these four categories of T<sub>H</sub> responsiveness, and within each category, quantitatively sum-

marizes the IL-2 results obtained from each stimulant by plotting individual data points and mean values. The data shown are for a supernatant dilution of 1:4; similar results were obtained at dilutions of 1:2 and 1:8. Among the 40 patients who were selectively unresponsive to FLU and TET (-/+), IL-2 production levels to FLU and TET were significantly below those of the HIV<sup>-</sup> controls (compare Fig. 2 C with A, and H with G;  $P < 0.01$  for FLU and  $P < 0.01$  for TET), and also significantly below those of the responsive HIV<sup>+</sup> patients (compare Fig. 2 C with B, and H with G;  $P < 0.05$  for FLU and  $P < 0.05$  for TET). IL-2 production did not differ significantly among these three groups for responses to ALLO and PHA (Fig. 2, K-M and P-R). The 12 patients who responded only to

Table I. Fraction and Percentage of Unresponsive Patients to FLU, TET, ALLO, and PHA

Donor status	Tested by IL-2 production				Tested by proliferation			
	FLU	TET	ALLO	PHA	FLU	TET	ALLO	PHA
HIV <sup>+</sup> patients	62/74 84%	62/74 84%	22/74 30%	10/74 14%	39/49 80%	39/49 80%	11/49 22%	2/49 4%
HIV <sup>-</sup> controls	1/70 1%	1/70 1%	0/70 0%	0/67 0%	3/58 5%	2/57 3%	0/58 0%	0/56 0%




Figure 2. Mean and individual values for IL-2 production (detected at a supernatant dilution of 1:4) by PBL from HIV<sup>-</sup> (A, F, K, P) and HIV<sup>+</sup> (all other panels) individuals to: FLU (A-E); TET (F-J); ALLO (K-O); or PHA (P-T). +/+/+ indicates individuals whose PBL generated normal IL-2 responses to all four stimuli; -/+/+ indicates individuals whose PBL were selectively deficient in IL-2 responses to FLU and TET; -/-/+ indicates individuals whose PBL were deficient in IL-2 responses to FLU, TET, and ALLO, but not to PHA; -/-/- indicates individuals whose PBL were deficient in response to all four stimuli. Number of donors in each category is shown in ( ) in donor status column. In some of the panels (for example, 69 HIV<sup>-</sup> and 40 -/+/+ donors), overlapping values did not permit showing of all points.

PHA by IL-2 production (-/-/+) exhibited a significant reduction in mean counts per minute for ALLO when compared with the ALLO response of -/+/+ or +/+/+ patients or the HIV<sup>-</sup> donors (compare Fig. 2 N with K-M;  $P < 0.05$ ). The mean counts per minute for response to PHA, however, was similar among these groups. Finally, the 10 patients who were unresponsive to any of these four stimuli (-/-/-) exhibited a significant reduction in counts per minute for IL-2 production to PHA compared with the groups of patients who responded to PHA (compare Fig. 2 E with P-S;  $P < 0.05$ ). The results of Fig. 2 verify that these 74 WR 1 and WR 2 patients can be divided into four functional categories, based on T<sub>H</sub> responses to recall antigens, alloantigens, and a T cell mitogen.

Most of the patients in the study were also tested for delayed skin reactions to a panel of antigens including *Candida albicans*, tetanus toxoid, mumps, trichophyton, and purified protein derivative (PPD). Of the 63 WR 1 and 2 patients who were tested for both in vitro IL-2 production and for in vivo skin reactions to TET, 51 were unresponsive to TET by IL-2 production, whereas only 8 were unresponsive to TET by skin test (data not shown).

**Lack of correlation between T<sub>H</sub> function and either CD4<sup>+</sup> cell number or WR 1 and WR 2.** Contingency tables were prepared in which the numbers of patients in each functional category are shown for three ranges of CD4<sup>+</sup> cell numbers (Table II) and for WR 1 and WR 2 patients (Table III). Statistical analysis of the data in the R × C contingency comparison of Table II indicates that there was no correlation between any of the four T<sub>H</sub> response patterns (by IL-2 or proliferation) and the CD4<sup>+</sup> cell numbers. A similar analysis of the frequency data for the four T<sub>H</sub> categories by either the IL-2 production or proliferation assays for T<sub>H</sub> function indicates no correlation of function with WR 1 or WR 2 (Table III).

Table II. Lack of Correlation between T<sub>H</sub> Function and CD4<sup>+</sup> Cell Number

Functional category*	Range of CD4 <sup>+</sup> cell numbers (/mm <sup>3</sup> )			Total	Statistics
	400-600	600-800	>800		
<b>By IL-2 production</b>					
+/+/+	6	2	4	12	
-/+/+	14	16	10	40	
-/-/+	4	5	3	12	
-/-/-	7	2	1	10	$\chi^2 = 4.60$
Total	31	25	18	74	$P > 0.50$
<b>By proliferation</b>					
+/+/+	3	2	5	10	
-/+/+	11	13	4	28	
-/-/+	3	4	2	9	
-/-/-	2	0	0	2	$\chi^2 = 7.73$
Total	19	19	11	49	$P > 0.25$

\* +/+/+ indicates patients who responded to FLU, TET, ALLO, and PHA; -/+/+ indicates patients who responded to ALLO and PHA, but not to FLU and TET; -/-/+ indicates patients who responded to PHA, but not to FLU, TET, or ALLO; -/-/- indicates patients who did not respond to any of the four stimuli.

**Time-dependent changes in T<sub>H</sub> function.** The data illustrated in Figs. 1 and 2 suggest a progression from the functional stage in which the patient is responsive to all four stimuli (+/+/+), through a selective loss in T<sub>H</sub> function to recall antigens such as FLU and TET (-/+/+), followed by loss of response to ALLO (-/-/+), and finally to a totally unresponsive state (-/-/-). However, these data, as well as the data collected on most of our 74 patients, represent only one point in

Table III. Lack of Correlation between T<sub>H</sub> Function and Walter Reed Stage (WR)

Functional category*	WR			Statistics
	1	2	Total	
<b>By IL-2 production</b>				
+/+/+	6	6	12	
-/+/+	22	18	40	
-/-/+	6	6	12	
-/-/-	8	2	10	$\chi^2 = 1.71$
Total	42	32	74	$P > 0.50$
<b>By proliferation</b>				
+/+/+	3	7	10	
-/+/+	15	13	28	
-/-/+	5	4	9	
-/-/-	2	0	2	$\chi^2 = 3.84$
Total	25	24	49	$P > 0.25$

\* +/+/+ indicates patients who responded to FLU, TET, ALLO, and PHA; -/+/+ indicates patients who responded to ALLO and PHA, but not to FLU and TET; -/-/+ indicates patients who responded to PHA, but not to FLU, TET, or ALLO; -/-/- indicates patients who did not respond to any of the four stimuli.

time for each individual's progression toward symptomatic AIDS. As part of a longitudinal study of  $T_H$  function, we have collected and cryopreserved serial blood samples from a limited number of asymptomatic, HIV<sup>+</sup> individuals for the past 5 yr. If the patterns of unresponsiveness shown in Fig. 1 are sequential and represent a progressive loss of  $T_H$  function, then it should be possible to detect a sequential loss of  $T_H$  function with time in a given patient.

Fig. 3 illustrates a longitudinal comparison of FLU-stimulated IL-2 production by PBL from three donors who have been involved in this study for several years. PBL from the donor shown in Fig. 3 A were cryopreserved in 1983 and in 1988. This donor remained asymptomatic throughout the 4.5-yr period and had 573/mm<sup>3</sup> of CD4<sup>+</sup> cells at the time of the last blood collection. PBL from the donor in Fig. 3 B were cryopreserved in 1984 and in 1987. This donor experienced a reduction in CD4<sup>+</sup> cells (from 500 to 139/mm<sup>3</sup>) during this period, but was not diagnosed with lymphadenopathy or AIDS. PBL from the donor in Fig. 3 C were cryopreserved in 1985 and 1988. During this time interval, this donor experienced a reduction in CD4<sup>+</sup> cells from 715 to 235/mm<sup>3</sup>, but remained otherwise asymptomatic. The two preparations of PBL from each of these three donors were thawed simultaneously and tested for their ability to generate IL-2 in response to stimulation with FLU and TET (donor in Fig. 3 A) or with FLU only (donors in Fig. 3, B and C). These results (Fig. 3) demonstrate that in these three donors there was a time-dependent, selective loss of  $T_H$  function to CD4-dependent antigens such as FLU and TET and suggest that a similar pattern of selective loss of  $T_H$  response occurred in the other donors who were selectively defective in their responses to FLU and TET. It should be noted that the time-dependent loss of  $T_H$




Figure 3. IL-2 production by PBL from three HIV<sup>+</sup> individuals taken at different time intervals during progressive loss of  $T_H$  cell function. PBL were unstimulated ( $\nabla$ ) (mean value of the two unstimulated cultures), or stimulated with FLU ( $\Delta$ ,  $\blacktriangle$ ) or TET ( $\circ$ ,  $\bullet$ ). Open symbols indicate the response from the earlier bleed; closed symbols indicate from the later bleed. The numbers in each panel indicate the two dates that blood was drawn from a donor to be used in the comparative test. Both samples of the PBL from each donor were cryopreserved and tested in the same experiment.




Figure 4. IL-2 production by PBL from a single asymptomatic, HIV<sup>+</sup> individual (WR 1) taken at three 4-mo time intervals. PBL were unstimulated ( $\nabla$ ) or stimulated with FLU ( $\bullet$ ), TET ( $\circ$ ), ALLO ( $\blacktriangle$ ), or PHA ( $\blacktriangledown$ ). The numbers in each panel indicate the dates that the blood was drawn and tested. CD4<sup>+</sup> and CD8<sup>+</sup> cell numbers are shown in the lower part of each panel.

response to FLU and TET in the donor in Fig. 3 A was not due to a critically low number of CD4<sup>+</sup> cells. Due to limitations on the number of cryopreserved PBL available, it was not possible to test these individuals for  $T_H$  function to ALLO or PHA. It should also be noted that PBL from HIV<sup>-</sup> donors frozen in 1983 and tested in 1988 still retained a strong  $T_H$  function to FLU and TET (data not shown).

To obtain a more precise time estimate for development of  $T_H$  unresponsiveness, an asymptomatic, HIV<sup>+</sup> donor was studied at 4-mo intervals to detect possible loss of  $T_H$  function. Fig. 4 illustrates the titration curves for IL-2 production by PBL stimulated with FLU, TET, ALLO, or PHA. In March 1988, the patient was marginally responsive to FLU and TET, but was strongly responsive to ALLO (Fig. 4 A). (PHA was not tested in this experiment.) During the next 8 mo, the patient's FLU and TET responses continued to decline to unstimulated levels, whereas the ALLO and PHA responses remained strong (Fig. 4, B and C). During this time interval, the patient did not develop any symptoms and CD4<sup>+</sup> and CD8<sup>+</sup> T cell numbers increased slightly. In all three experiments, PBL from HIV<sup>-</sup> control donors generated potent  $T_H$  responses to all four stimuli (data not shown). These data demonstrate that loss of  $T_H$  function to recall antigens can occur abruptly and is not neces-

sarily associated with symptomatic changes nor with a reduction in CD4<sup>+</sup> cell numbers.

To further investigate possible progression in T<sub>H</sub> defects, we have studied IL-2 responses of PBL from patients in the more advanced WR 3 to WR 6. If the failure to produce IL-2 in response to ALLO represents T<sub>H</sub> dysfunction associated with more advanced stages of AIDS progression, then a larger proportion of WR 3 to WR 6 patients should be unresponsive to FLU or TET, and also to ALLO. The proportions of IL-2 responses by 22 patients are summarized in Table IV and are compared with the proportions of responses by our 74 WR 1 and WR 2 patients using the same two stimuli. The majority of the WR 3 to WR 6 failed to respond to FLU or ALLO (64%) compared with only 30% of the WR 1 and WR 2 patients who failed to respond to both stimuli. The statistical likelihood that these frequency differences between WR 1 and WR 2 and WR 3 to WR 6 patients were due to chance was < 1%. Thus, these results support the hypothesis that the T<sub>H</sub> functional phases shown in Figs. 1 and 2 represent a sequential progression of immune dysfunction that is associated with progression toward AIDS.

## Discussion

Other studies have reported that the T cell responses to recall antigens may be defective in some HIV<sup>+</sup> patients who do not have AIDS (17–20). Our laboratory (11) has previously demonstrated a selective defect in CTL responses to FLU but not to ALLO in asymptomatic, HIV<sup>+</sup> individuals. Because the deficient CTL response to FLU could be corrected in vitro by recombinant IL-2, the CTL defect appeared to reflect an underlying deficiency in CD4<sup>+</sup> T<sub>H</sub> function. A similar IL-2-correctable defect in CTL function has been reported in patients with symptomatic AIDS (21). These findings indicate that: (a) IL-2 is a helper lymphokine for human CTL generation; and (b) this lymphokine is deficient in HIV-infected individuals. The present study measures T<sub>H</sub> function directly by assessing IL-2 production and extends these findings by: (a) identifying a series of three distinct T<sub>H</sub> functional defects in asymptomatic patients; (b) demonstrating a time-dependent progressive and selective loss of T<sub>H</sub> function in individual asymptomatic patients; and (c) attempting to correlate these defects with clinical staging criteria.

The three different patterns of T<sub>H</sub> dysfunction identified among these asymptomatic patients were (a) a selective loss of T<sub>H</sub> function to recall antigens such as FLU and TET, but retention of T<sub>H</sub> function upon stimulation to ALLO or PHA (54%); (b) an absence of T<sub>H</sub> function to the recall antigens and to ALLO, but preserved responses to PHA (16%); and (c) a

lack of response to all of the stimuli (14%). Furthermore, 16% of these asymptomatic patients were responsive to all of the stimuli. None of the three patterns of T<sub>H</sub> dysfunction could be attributed to a critical reduction in CD4<sup>+</sup> cell numbers. PBL from many of the same patients who were positive to tetanus by skin test were negative by IL-2 production and by [<sup>3</sup>H]thymidine incorporation after in vitro stimulation with tetanus. This discrepancy in the in vivo and in vitro immunological tests could be due to one of several possibilities: (a) the in vitro tests introduce artifacts that are not observed by in vivo delayed skin reactions; (b) the in vitro tests utilize different functional subsets of T lymphocytes and/or APC than the delayed skin reaction; or (c) the in vitro IL-2 production and [<sup>3</sup>H]thymidine incorporation assays are more sensitive and detect immune dysfunction before the delayed skin reaction. We favor the third hypothesis because we have observed a progression in loss of IL-2 production to recall antigens as a function of time, which in WR 1 and WR 2 patients is not correlated with a decline in CD4<sup>+</sup> cell numbers. Thus, it is likely that our in vitro data reflect an early stage of CD4<sup>+</sup> T<sub>H</sub> dysfunction. The observation that none of 22 advanced WR 3 to WR 6 patients responded by IL-2 production to FLU (compared with the 16% of WR 1 and WR 2 patients who responded to the two recall antigens) supports the hypothesis that loss of T<sub>H</sub> function to FLU and TET is an early sign of immune dysfunction that is progressive. Furthermore, our observation that a higher percentage (64%) of more advanced patients failed to respond to FLU and ALLO than did WR 1 and WR 2 patients supports our interpretation that the absence of T<sub>H</sub> responses to ALLO represents advancing stages of more severe immune dysfunction. Recently, using T lymphocytes and APC from healthy, HIV<sup>-</sup> donors, we have demonstrated that T<sub>H</sub> responses to FLU and TET require CD4<sup>+</sup> T<sub>H</sub> cells and autologous APC. In contrast, T<sub>H</sub> responses to ALLO can utilize three different T<sub>H</sub>-APC pathways: (a) CD4<sup>+</sup> T<sub>H</sub> and autologous APC that process and present alloantigenic HLA determinants in association with self-HLA products; (b) CD4<sup>+</sup> T<sub>H</sub> that recognize ALLO directly on allogeneic APC; and (c) CD8<sup>+</sup> T cells that recognize ALLO directly on allogeneic APC (13).<sup>2</sup> Likewise, PHA responses can be mediated by both CD4<sup>+</sup> and CD8<sup>+</sup> T cells (12). Therefore, the selective defect in T<sub>H</sub> responses to FLU and TET in 84% of our patients can be attributed to an early immune dysfunction that selectively affects CD4<sup>+</sup> T<sub>H</sub> and/or autologous APC. CD8<sup>+</sup> T cells would be unaffected and could respond to ALLO and PHA.

The loss in T<sub>H</sub> function in asymptomatic patients is not due to a critical reduction in CD4<sup>+</sup> cell numbers and, therefore, must be attributed to some other mechanism(s). CD4<sup>+</sup> cells could be infected without being killed and such infected cells would be nonfunctional (22). However, this possibility appears to be unlikely because in situ hybridization studies indicate that the frequency of infected leukocytes is less than 1/10<sup>3</sup> (23). An alternative possible mechanism is suggested by the recent report that the sera of some AIDS patients (24), as well as some asymptomatic HIV<sup>+</sup> individuals (25), contain an antibody that reacts with a nonpolymorphic component of human MHC class II molecules. These antibodies can block antigen-stimulated proliferative responses of CD4<sup>+</sup> T cells from HIV<sup>-</sup> individuals (24). Thus, these autoantibodies might block MHC class II self-restricted interactions between CD4<sup>+</sup> and APC required for FLU and TET responses. A third possibility is that HIV infection activates a regulatory cell that selec-

Table IV. Evidence for a Progressive and Sequential Loss of T<sub>H</sub> Function in More Advanced Walter Reed Stages (WR)\*

T <sub>H</sub> response to		Fraction and percentage of patients in	
FLU	ALLO	WR 1 and 2	WR 3–6
+	+	12/74 (16%)	0/22 (0%)
–	+	40/74 (54%)	8/22 (36%)
–	–	22/74 (30%)	14/22 (64%)

\*  $\chi^2 = 9.82$ ;  $P < 0.07$ .

tively suppresses CD4-mediated responses (26). Despite the fact that regulatory cells that selectively suppress CD4<sup>+</sup> T<sub>H</sub> function have been described in murine models of T<sub>H</sub> dysfunction (27, 28), we have not yet detected such a regulatory cell in HIV patients. Fourth, because HIV infects CD4<sup>+</sup> monocytes and macrophages (29, 30), and because this early defect is limited to antigens that require CD4<sup>+</sup> T<sub>H</sub> cells and autologous APC, it is possible that antigen-presenting function rather than T<sub>H</sub> function is defective in these patients. However, preliminary studies from our laboratory comparing the T<sub>H</sub> and APC functions of cells from individual, asymptomatic patients, before and after the loss of T<sub>H</sub> response to FLU and TET, have not shown any defect in APC function (manuscript in preparation). Thus, the mechanism(s) responsible for the early T<sub>H</sub> dysfunction in asymptomatic, HIV<sup>+</sup> individuals remains unresolved, but is under investigation.

We have defined responsive and unresponsive patients by the statistical method described in Methods. Stimulation indices of 2.0 or greater have also been used to define responsiveness in other studies (31). We compared both methods in the present study, and found no differences in the percentage of unresponsive donors for the [<sup>3</sup>H]thymidine assay by either approach. Thus, 80% of the WR 1 and WR 2 patients were unresponsive to FLU and TET, irrespective of which method was used. However, we did find that a lower percentage (57%) of patients were unresponsive to FLU and TET if we used a stimulation index of 2.0 rather than 3 SD above the mean background method (84%). Regardless of which method is used and whether T<sub>H</sub> function is measured by IL-2 production or by [<sup>3</sup>H]thymidine incorporation, a majority of WR 1 and WR 2 patients are unresponsive to recall antigens.

Despite our finding that the WR 1 and WR 2 patients exhibit CD4<sup>+</sup> T<sub>H</sub> defects, they do not have opportunistic infections. It is possible that the loss of CD4<sup>+</sup> T<sub>H</sub> function is responsible for a nonprogressive period after HIV infection. For example, the observation that CD4<sup>+</sup> T cells must be activated for HIV to be infectious (32, 33) is compatible with the hypothesis that a nonprogressive period could be associated with a condition of CD4<sup>+</sup> T<sub>H</sub> unresponsiveness. If CD4<sup>+</sup> T<sub>H</sub> were unresponsive to antigenic stimulation, further progression toward AIDS by more extensive infection of the remaining uninfected CD4<sup>+</sup> T cells might be impaired. Thus, this unresponsive condition may indeed be protective and represent a period in which down-regulation of CD4<sup>+</sup> T<sub>H</sub> function inhibits further spread of HIV infection.

Because none of the four distinct patterns of T<sub>H</sub> function identified in HIV<sup>+</sup> asymptomatic individuals were correlated with either CD4<sup>+</sup> cell numbers nor with WR staging, we suggest that an in vitro test for T<sub>H</sub> function be incorporated into HIV staging criteria. This assay could include IL-2 production to one or more recall antigens to assess CD4<sup>+</sup> T<sub>H</sub>-self APC interactions and include the IL-2 responses to ALLO and PHA to detect the presence of more severe immune functional defects.

## Acknowledgments

The authors express their thanks to Dr. Robert Yarchoan, Clinical Oncology Unit, NCI, NIH, Bethesda, MD, and to Dr. Barry Handwerker, Rheumatology Division, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, for reviewing the

manuscript, and to Dr. Satish Muluk, Experimental Immunology Branch, NCI, NIH, Bethesda, MD, for statistical consultation.

*Note added in proof.* Since submission of this manuscript, an additional 206 WR 1 and WR 2 patients have been tested for T helper function for IL-2 production in response to FLU, TET, and ALLO (but not to PHA). 82/206 (40%) responded to all stimuli: 88/206 (43%) failed to respond to FLU and TET, but responded to ALLO; and 36/206 (17%) failed to respond to any of the three stimuli.

## References

1. Lane, H. C., H. Masur, L. C. Edgar, G. Whalen, A. R. Rook, and A. S. Fauci. 1983. Abnormalities of B cell activation and immunoregulation in patients with the acquired immune deficiency syndrome. *N. Engl. J. Med.* 309:453-458.
2. Fahey, J. L., H. Prince, M. Weaver, J. Groopman, B. Visscher, T. Schwartz, and R. Detels. 1984. Quantitative changes in T helper or T suppressor/cytotoxic lymphocyte subsets that distinguish acquired immune deficiency syndrome from other immune subset disorders. *Am. J. Med.* 76:95-100.
3. Lane, H. C., H. Masur, E. P. Gelmann, D. L. Longo, R. G. Steis, T. Chused, G. Whalen, L. C. Edgard, and A. S. Fauci. 1985. Correlation between immunological function and clinical subpopulations of patients with the acquired immune deficiency syndrome. *Am. J. Med.* 78:417-422.
4. Bowen, D. L., H. C. Lane, and A. S. Fauci. 1985. Immunopathogenesis of the acquired immunodeficiency syndrome. *Ann. Intern. Med.* 103:704-709.
5. deWolf, F., J. M. A. Lange, J. T. M. Houweling, R. A. Coutinho, P. T. Schellekens, J. van der Noordaa, and J. Goudsmit. 1988. Numbers of CD4<sup>+</sup> cells and the levels of core antigens of and antibodies to the human immunodeficiency virus as predictors of AIDS among seropositive homosexual men. *J. Infect. Dis.* 158:615-622.
6. Mathur-Wagh, U., D. Mildvan, and R. T. Senie. 1985. Follow-up at 4½ years on homosexual men with generalized lymphadenopathy. *N. Engl. J. Med.* 313:1542-1543.
7. Goedert, J. J., R. J. Biggar, S. H. Weiss, M. E. Eyster, M. Melbye, S. Wilson, H. M. G. Ginzburg, R. G. Grossman, R. A. Digioia, W. C. Sanchez, J. A. Giron, P. Ebbesen, R. C. Gallo, and W. A. Blattner. 1986. Three-year incidence of AIDS in five cohorts of HTLV-III-infected risk group members. *Science (Wash. DC)*. 231:992-995.
8. Melbye, M., R. J. Biggar, P. Ebbesen, C. Neuland, J. J. Goedert, V. Faber, I. B. Lorenzen, P. Skinhi, R. C. Gallo, and W. A. Blattner. 1986. Long term seropositivity for human T-lymphotropic virus type III in homosexual men without the acquired immunodeficiency syndrome: development of immunologic and clinical abnormalities. *Ann. Intern. Med.* 104:496-500.
9. Taylor, J. M. G., K. Schwartz, and R. Detels. 1986. The time from infection with human immunodeficiency virus (HIV) to the onset of AIDS. *J. Infect. Dis.* 154:694-697.
10. El-Sadr, W., M. Marmor, S. Zolla-Pazner, R. E. Stahl, M. Lyden, D. Williams, S. D'Odofrio, S. H. Weiss, and W. C. Saxinger. 1987. Four-year prospective study of homosexual men: correlation of immunologic abnormalities, clinical status, and serology to human immunodeficiency virus. *J. Infect. Dis.* 155:789-793.
11. Shearer, G. M., D. C. Bernstein, K. S. Tung, C. S. Via, R. Redfield, S. Z. Salahuddin, and R. C. Gallo. 1986. A model for the selective loss of major histocompatibility complex self-restricted T cell immune response during the development of acquired immune deficiency syndrome (AIDS). *J. Immunol.* 137:2514-2521.
12. Meuer, S. C., R. E. Hussey, A. C. Penta, K. A. Fitzgerald, B. M. Stadler, S. F. Schlossman, and E. S. Reinherz. 1982. Cellular origin of interleukin 2 (IL 2) in man: evidence for stimulus-restricted IL 2 production by T4<sup>+</sup> and T8<sup>+</sup> T lymphocytes. *J. Immunol.* 129:1076-1079.
13. Via, C. S., G. Tsokos, and G. M. Shearer. 1989. Multiple

pathways of human T helper (T<sub>H</sub>) cell activation following in vitro stimulation with alloantigen. *FASEB (Fed. Am. Soc. Exp. Biol.) J.* 3:A366. (Abstr.)

14. Redfield, R. R., D. C. Wright, and E. C. Tramont. 1986. The Walter Reed staging classification for HTLV-III/LAV infection. *N. Engl. J. Med.* 314:131-132.

15. Uchiyama, T., S. Broder, and T. A. Waldmann. 1981. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac(+) cells. *J. Immunol.* 126:1393-1397.

16. Snedecor, G. W., and W. G. Cochran. 1980. *Statistical Methods*. 7th Ed. The University of Iowa Press, Ames, IA.

17. Lane, H. C., J. M. Depper, W. C. Greene, G. Whalen, T. A. Waldmann, and A. S. Fauci. 1985. Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome: evidence for a selective defect in soluble antigen recognition. *N. Engl. J. Med.* 313:79-84.

18. Smolen, J. S., P. Bettleheim, U. Koller, S. McDougal, W. Graninger, T. A. Luger, W. Knapp, and K. Lechner. 1985. Deficiency of the autologous mixed lymphocyte reaction in patients with classic hemophilia treated with comminuted Factor VIII concentrate: correlation with T cell subsets distribution, antibodies to lymphadenopathy-associated or human T lymphotropic virus, and analysis of the cellular basis of the deficiency. *J. Clin. Invest.* 75:1828-1834.

19. Garbrecht, F. C., G. W. Siskind, and M. E. Wexler. 1987. Lymphocyte transformation induced by autologous cells. XVIII. Impaired autologous mixed lymphocyte reaction in subjects with AIDS-related complex. *Clin. Exp. Immunol.* 67:245-251.

20. Giorgi, J. V., J. L. Fahey, D. C. Smith, L. E. Hultin, H. Cheng, R. T. Mitsuyasu, and R. Detels. 1987. Early effects of HIV on CD4 lymphocytes in vivo. *J. Immunol.* 138:3725-3730.

21. Rook, A. H., H. Masur, H. C. Lane, W. Frederick, T. Kasahara, A. M. Macher, J. Y. Djeu, J. F. Manischewitz, L. Jackson, A. S. Fauci, and G. V. Quinnin. 1983. Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with acquired immunodeficiency syndrome. *J. Clin. Invest.* 72:398-403.

22. Fauci, A. S. 1987. AIDS: immunopathogenetic mechanism and research strategies. *Clin. Res.* 35:503-510.

23. Harper, M. C., L. M. Marselle, R. C. Gallo, and F. Wong-Staal. 1986. Detection of lymphocytes expressing human T-lymphotropic virus type III in lymph nodes and peripheral blood from infected individuals by in situ hybridization. *Proc. Natl. Acad. Sci. USA.* 83:772-776.

24. Golding, H., F. A. Robey, F. T. Gates, III, W. Linder, P. R. Beining, T. Hoffman, and B. Golding. 1988. Identification of homologous regions in human immunodeficiency virus I gp41 and human MHC class II I domain. I. Monoclonal antibodies against the gp41-derived peptide and patient's sera react with native HLA class II antigens, suggesting a role for autoimmunity in the pathogenesis of acquired immune deficiency syndrome. *J. Exp. Med.* 167:914-923.

25. Golding, H., G. M. Shearer, K. Hillman, P. Lucas, J. Manischewitz, R. A. Zajac, M. Clerici, R. E. Gress, R. N. Boswell, and B. Golding. 1989. Common epitope in HIV I-GP41 and HLA class II elicits immunosuppressive autoantibodies capable of contributing to immune dysfunction in HIV-infected individuals. *J. Clin. Invest.* 83:1430-1435.

26. Via, C. S., and G. M. Shearer. 1988. T-cell interaction in autoimmunity: insights from a murine model of graft-versus-host disease. *Immunol. Today.* 9:207-212.

27. Moser, M., T. Mizuochi, S. O. Sharrow, A. Singer, and G. M. Shearer. 1987. Graft-vs-host reaction limited to a class II MHC difference results in a selective deficiency in L3T4<sup>+</sup> but not in Lyt2<sup>+</sup> T helper cell function. *J. Immunol.* 138:1355-1362.

28. Via, C. S., and G. M. Shearer. 1988. Functional heterogeneity of L3T4<sup>+</sup> T cells in MRL-lpr/lpr mice. L3T4<sup>+</sup> T cells suppress major histocompatibility complex-self-restricted L3T4<sup>+</sup> T helper cell function in association with autoimmunity. *J. Exp. Med.* 168:2165-2181.

29. Prince, H. E., D. J. Moody, B. I. Shubin, and J. L. Fahey. 1985. Defective monocyte function in acquired immunodeficiency syndrome (AIDS). Evidence from a monocyte-dependent T-cell proliferative system. *J. Clin. Immunol.* 5:21-25.

30. Gartner, S., P. Markovitz, D. M. Markovitz, M. H. Kaplan, R. C. Gallo, and M. Popovic. 1986. The role of mononuclear phagocytes in HTLV-III/LAV infection. *Science (Wash. DC).* 233:215-219.

31. Schrier, R. D., J. W. Gnann, Jr., R. Landes, C. Lockshin, D. Richman, A. McCutchan, C. Kennedy, M. B. A. Oldstone, and J. A. Nelson. 1989. T cell recognition of HIV synthetic peptides in a natural infection. *J. Immunol.* 142:1166-1176.

32. McDougal, J. S., A. Mawle, S. P. Cort, J. K. A. Nicholson, G. D. Cross, J. A. Scheppler-Campbell, D. Hicks, and J. Slish. 1985. Cellular tropism of the human retrovirus HTLV-III/LAV. I. Role of T cell activation and expression of the T4 antigen. *J. Immunol.* 135:3151-3162.

33. Folks, T. M., J. Kelly, S. Benn, A. Kinter, J. Justement, J. Gold, R. Redfield, K. W. Sell, and A. S. Fauci. 1986. Susceptibility of normal human lymphocytes to infection with HTLV-III/LAV. *J. Immunol.* 136:4049-4053.